Antifungal agent that inhibits fungal wall synthesis of 1,3 Beta-D-glucan.
Activity against candida species and aspergillus species.
As effective as the use of liposomal amphotericin B as an antifungal agent in patients with fever and neutropenia.
Compared to liposomal amphotericin B in febrile neutropenic patients it is a safer agent with improved survival and improved response rates in patients with invasive fungal infections.
Among children, adolescents, and young adults with AML, prophylaxis with caspofungin compared with fluconazole resulted in a significant lower incidence of invasive fungal disease.